--- title: "CapForce (CFOR) stock listing, news and investor profile" url: "https://aibio.space/companies/capforce/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CapForce Inc. (OTC: CFOR), United States. Listing facts, related biotech companies and news on aibio.space." --- CFOR CapForce Inc. OTC · United States # CapForce (CFOR) news CapForce Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker CFOR, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest CapForce news We have not published a story on CapForce yet. When there is news, it will appear here. ## CapForce at a glance - **Ticker**: CFOR - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $143,781 ### Related companies - [OneMedNet](https://aibio.space/companies/onemednet/) NASDAQ: ONMD - [IQVIA HOLDINGS INC.](https://aibio.space/companies/iqvia/) NYSE: IQV - [UFP TECHNOLOGIES INC](https://aibio.space/companies/ufp-technologies/) NASDAQ: UFPT - [BIOFORCE NANOSCIENCES HOLDINGS, INC.](https://aibio.space/companies/bioforce-nanosciences/) OTC: BFNH - [QTREX Quantum](https://aibio.space/companies/qtrex-quantum/) NASDAQ: QTEX - [POSITRON CORP](https://aibio.space/companies/positron/) OTC: POSC - [Cadre Holdings](https://aibio.space/companies/cadre/) NYSE: CDRE - [Apyx Medical](https://aibio.space/companies/apyx-medical/) NASDAQ: APYX ### Also on OTC - [CytoDyn](https://aibio.space/companies/cytodyn/) CYDY - [Lotus Pharmaceuticals](https://aibio.space/companies/lotus-pharmaceuticals/) LTUS - [Opthea](https://aibio.space/companies/opthea/) CKDXF - [ANTHERA PHARMACEUTICALS INC](https://aibio.space/companies/anthera-pharmaceuticals/) ANTH - [EBR Systems](https://aibio.space/companies/ebr-systems/) EBRCZ - [CYANOTECH CORP](https://aibio.space/companies/cyanotech/) CYAN ## What CapForce does CapForce Inc., formerly OpGen, Inc., now describes its business as capital markets advisory and financial technology. It offers capital market listing sponsorship and listing consultancy services to mid-sized, growth-stage private companies, with a particular emphasis on issuers based in Asia, targeting market capitalization values between $1 billion and $10 billion. In December 2025 it acquired Sun Investment Enterprises Limited, which owns iCapX Sdn. Bhd., a Malaysian company that provides cap table management and related platform services. CapForce is progressing toward a next-generation global digital investment banking platform for cross-border securities trading, investment banking advisory and asset management. The company says it is actively providing listing sponsorship services to a single client. Before November 2023 the company was a precision medicine company focused on molecular diagnostics for infectious disease, through subsidiaries Curetis GmbH and Ares Genetics GmbH, which entered insolvency proceedings and were deconsolidated. | Product or program | What it is | Stage | |---|---|---| | Capital market listing sponsorship | Listing sponsorship and consultancy for mid-sized growth-stage private companies | actively providing services to a single client | | iCapX cap table platform | Cap table management and related platform services for customers | providing services to customers | | Digital investment banking platform | Global platform for cross-border trading, advisory and asset management | progressing toward launch | Summarised from the company's [10-K filed May 26, 2026](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/capforceinc_10k.htm). ## CapForce annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$30.2 million](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/) | [$5.2 million](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/) | | Research and development | [$6,585](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/) | [$48,820](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/) | | Net income (loss) | [$23.6 million](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/) | [$12.0 million](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/) | | Cash from operations | [-$1.2 million](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/) | [-$4.9 million](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/) | | Cash and equivalents | [$531,277](https://www.sec.gov/Archives/edgar/data/1293818/000182912626009079/) | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005672/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $143,781. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about CapForce What is the ticker symbol of CapForce? CapForce Inc. trades under the ticker CFOR on OTC. Where is CapForce listed? CapForce Inc. is listed on OTC. Which country or territory is CapForce listed under? Our directory records CapForce Inc. under United States. Does aibio.space cover CapForce? aibio.space lists CapForce Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does CapForce develop? CapForce Inc., formerly OpGen, Inc., now describes its business as capital markets advisory and financial technology. It offers capital market listing sponsorship and listing consultancy services to mid-sized, growth-stage private companies, with a particular emphasis on issuers based in Asia, targeting market capitalization values between $1 billion and $10 billion. What is Capital market listing sponsorship from CapForce? Capital market listing sponsorship: Listing sponsorship and consultancy for mid-sized growth-stage private companies Stage: actively providing services to a single client. What is iCapX cap table platform from CapForce? iCapX cap table platform: Cap table management and related platform services for customers Stage: providing services to customers. What was CapForce's revenue last year? $30.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is CapForce profitable? CapForce Inc. reported net income of $23.6 million for the fiscal year ended Dec 31, 2025, and used $1.2 million of cash in operations, per its annual report to the SEC. How much does CapForce spend on research and development? $6,585 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does CapForce have? $143,781 in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: CapForce Members talk about CapForce (CFOR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at CapForce, newest first. Each line links the filing it comes from. 1. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1293818/000182912626008886/capforceinc_nt10q.htm) 2. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1293818/000182912626005351/capforceinc_nt10q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:CFOR on TradingView](https://www.tradingview.com/symbols/OTC-CFOR/). ## Listing details CapForce Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker CFOR, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: CapForce Inc. - **Ticker**: CFOR - **Listing**: OTC - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/capforce/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CapForce (CFOR) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/capforce/